Status:
COMPLETED
Beta-Blocker in Chronic Obstructive Pulmonary Disease (COPD) Study
Lead Sponsor:
Waikato Hospital
Collaborating Sponsors:
Waikato Hospital Research Fund
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
40-100 years
Phase:
NA
Brief Summary
Smoking causes both smoking related lung disease (COPD) and ischaemic heart disease. These are very common conditions and many patients have both diseases. Beta-blocker drugs are extensively used in t...
Eligibility Criteria
Inclusion
- Clinical diagnosis of COPD
- \> 40 years of age
- \> 15 pack year smoking history
Exclusion
- Contra-indication to beta-blocker use
- Severe COPD FEV1 \< 30% or 1 L
- Not responsive the methacholine
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2007
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT00745043
Start Date
May 1 2005
End Date
August 1 2007
Last Update
July 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Respiratory Medicine
Hamilton, Waikato Region, New Zealand, 3204